RecruitingPhase 2NCT02579967
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Studying OBSOLETE: Common variable immunodeficiency due to TNFR deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Dimana Dimitrova, M.D.National Cancer Institute (NCI)
- Intervention
- Immunosuppression Only Conditioning -Closed with amendment L(drug)
- Enrollment
- 354 enrolled
- Eligibility
- 4-75 years · All sexes
- Timeline
- 2015 – 2036
Study locations (2)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- National Marrow Donor Program, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02579967 on ClinicalTrials.govOther trials for OBSOLETE: Common variable immunodeficiency due to TNFR deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05193552Usage of Spirometry in Managing IgG Therapy in CVID with Airway DiseaseUniversity of Alabama at Birmingham
- ENROLLING BY INVITATIONPHASE2NCT05593588Senolytics Treatment of Interstitial Lung Disease in Common Variable ImmunodeficiencyAvni Joshi
See all trials for OBSOLETE: Common variable immunodeficiency due to TNFR deficiency →